Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 3/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.36 |
| ▸ | YWHAH | Q04917 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6091171 | 0.99 | KDM4E (0.39) | KDM4EPPARGRXFP1IRAK4ALDH1A1 | |
| SCHEMBL6093291 | 0.99 | KDM4E (0.39) | KDM4EPPARGRXFP1IRAK4ALDH1A1 | |
| SCHEMBL6093287 | 0.93 | KDM4E (0.37) | KDM4EPPARGRXFP1IRAK4ALDH1A1 | |
| SCHEMBL6092717 | 0.93 | RXFP1 (0.40) | PPARGRXFP1TP53 | |
| SCHEMBL6090174 | 0.92 | TP53 (0.41) | KDM4ERXFP1IRAK4PTGER1TP53 | |
| SCHEMBL6091080 | 0.87 | HDAC1 (0.42) | PPARGSLC2A1TP53 | |
| SCHEMBL6091713 | 0.86 | YWHAH (0.40) | PPARGALDH1A1YWHAHSLC2A1TP53 | |
| SCHEMBL6091726 | 0.85 | YWHAH (0.41) | PPARGALDH1A1YWHAHSLC2A1TP53 | |
| SCHEMBL6091727 | 0.84 | YWHAH (0.40) | PPARGALDH1A1YWHAHSLC2A1TP53 | |
| SCHEMBL6091457 | 0.83 | GRIN1 (0.41) | PPARGTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060160879-A1 | Indoles useful in the treatment of inflammation | BIOLIPOX AB (SE) | 2006-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160879-A1 | Indoles useful in the treatment of inflammation | IDO1, PTGS1, IDO2 | KDM4E 1962/4885PPARG 481/4885RXFP1 106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.